<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2396">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04623021</url>
  </required_header>
  <id_info>
    <org_study_id>A108_02CVD2014</org_study_id>
    <nct_id>NCT04623021</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia</brief_title>
  <official_title>An Open-label, Randomized, Multicenter, Controlled Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of CKD-314 (Nafabelltan)&#xD;
      compared to standard of care (SOC), with respect to clinical status assessed by a 7-point&#xD;
      ordinal scale in hospitalized adult patients diagnosed with COVID-19 pneumonia&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 25, 2020</start_date>
  <completion_date type="Actual">December 12, 2020</completion_date>
  <primary_completion_date type="Actual">December 12, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to clinical improvement</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Time to clinical improvement (TTCI) was defined as time (days) from randomization to a decline of 2 categories on the seven-category ordinal scale of clinical status or live discharge from the hospital, whichever came first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to recovery</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Day of recovery is defined as the first day on which the subject satisfies one of the following: 1) Not hospitalized with resumption of normal activities; 2) Not hospitalized, but unable to resume normal activities; 3) Hospitalization, not requiring supplemental oxygen- no longer required ongoing medical care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with clinical improvement as defined by live discharge from hospital or a decline of 2 categories on the seven-category ordinal scale of clinical status</measure>
    <time_frame>Day 4, 7, 11, 14 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with recovery as defined as the subject satisfies one of the following</measure>
    <time_frame>Day 4, 7, 11, 14 and 28</time_frame>
    <description>1) Not hospitalized with resumption of normal activities; 2) Not hospitalized, but unable to resume normal activities; 3) Hospitalization, not requiring supplemental oxygen- no longer required ongoing medical care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of clinical status assessed by 7-category ordinal scale</measure>
    <time_frame>Day 4, 7, 11, 14 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in National Early Warning Score (NEWS)</measure>
    <time_frame>Day 4, 7, 11, 14 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to National Early Warning Score (NEWS) of ≤ 2 which is maintained for 24 hours</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes on CT scan/X-ray</measure>
    <time_frame>Day 5, 11, 14 and 28</time_frame>
    <description>Measured as proportion of patients with improved, not changed or worsened CT scan/X-ray</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of CRP</measure>
    <time_frame>Day 4, 7, 11, 14 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to normalize the CRP</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Decrease to the level of &lt;10 mg/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of non-invasive ventilation or high flow oxygen use</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-invasive ventilation or high flow oxygen use</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Proportion of patients of non-invasive ventilation or high flow oxygen use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of supplement oxygen use</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of supplement oxygen use</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Proportion of patients of supplement oxygen use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of invasive ventilation or extracorporeal membrane oxygenation (ECMO) use</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of invasive ventilation or extracorporeal membrane oxygenation (ECMO) use</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Proportion of patients of invasive ventilation or extracorporeal membrane oxygenation (ECMO) use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-Day mortality</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of Care Treatment for COVID-19 Infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nafamostat + Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nafamostat mesylate on top of standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nafamostat Mesilate</intervention_name>
    <description>Administered intravenously as a continuous infusion</description>
    <arm_group_label>Nafamostat + Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women Aged ≥18 years&#xD;
&#xD;
          -  Hospitalized subjects who have confirmed COVID-19 infection and have evidence of&#xD;
             pneumonia:&#xD;
&#xD;
          -  Subjects who are eligible for diagnosis/evaluation to chest X-ray or chest CT&#xD;
&#xD;
          -  Women of childbearing potential (including women in post menopause for less than 2&#xD;
             years) must use a medically acceptable forms of birth control and agree to continue&#xD;
             its use during the study&#xD;
&#xD;
          -  Subjects (or legally authorized representative) should be able to understand and agree&#xD;
             to comply with the clinical trial and to provide a written consent document prior to&#xD;
             initiation of any study procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have a record of HIV or AIDS&#xD;
&#xD;
          -  Subject has a serious chronic disease&#xD;
&#xD;
          -  Active bleeding or ongoing clinical condition deemed at high risk of bleeding&#xD;
             contraindicating anticoagulant treatment&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Subjects with liver cirrhosis whose Child-Pugh score is B or C&#xD;
&#xD;
          -  Subjects who have liver disease abnormalities with ALT or AST &gt; 5 times ULN&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &lt; 30 ml/min (including patients receiving&#xD;
             hemodialysis or hemofiltration)&#xD;
&#xD;
          -  QTcB or QTcF &gt;500ms&#xD;
&#xD;
          -  Subjects who have clinically significant ventricular arrhythmias (ventricular&#xD;
             tachycardia, ventricular fibrillation) in medical history&#xD;
&#xD;
          -  Subjects with rapidly deteriorating clinical condition or low likelihood to complete&#xD;
             the study according to the investigator's opinion&#xD;
&#xD;
          -  Subjects who are not appropriate for the study, as the investigator's opinion&#xD;
&#xD;
          -  Subjects who have hypersensitivity to the investigational drug&#xD;
&#xD;
          -  Subjects participated in any other clinical trial (including drugs for the treatment&#xD;
             of COVID-19) 3 months prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>A108_02CVD2014 Site# 9</name>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A108_02CVD2014 Site# 26</name>
      <address>
        <city>Krasnoyarsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A108_02CVD2014 Site# 5</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A108_02CVD2014 Site# 8</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A108_02CVD2014 Site# 31</name>
      <address>
        <city>Ryazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A108_02CVD2014 Site# 25</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A108_02CVD2014 Site# 29</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A108_02CVD2014 Site# 30</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A108_02CVD2014 Site# 3</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A108_02CVD2014 Site# 4</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A108_02CVD2014 site#1</name>
      <address>
        <city>Ufa</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>January 31, 2021</last_update_submitted>
  <last_update_submitted_qc>January 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nafamostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

